UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2309701-2309701

2024

Volltextzugriff (PDF)

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Haematologica (Roma), 2024-02

2024

Volltextzugriff (PDF)

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Haematologica (Roma), 2023-06, Vol.108 (6), p.1671-1675

2023

Volltextzugriff (PDF)

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Chemotherapy (Basel), 2018-11, Vol.63 (4), p.220-224

2018

Volltextzugriff (PDF)

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

HemaSphere, 2022-06, Vol.6 (6), p.e727-n/a

2022

Volltextzugriff (PDF)

Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy

Chemotherapy (Basel), 2019-10, Vol.64 (2), p.110-114

2019

Volltextzugriff (PDF)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

HemaSphere, 2022-10, Vol.6 (Suppl), p.50-51

2022

Volltextzugriff (PDF)

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

Current oncology reports, 2019-02, Vol.21 (2), p.13-10, Article 13

2019

Volltextzugriff (PDF)

Lymphomas in pregnancy

Hematological oncology, 2023-06, Vol.41 (S1), p.70-74

2023

Volltextzugriff (PDF)

Bacterial infection-driven lymphomagenesis

Current opinion in oncology, 2022-09, Vol.34 (5), p.454-463

2022

Volltextzugriff (PDF)

Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

British journal of haematology, 2021-03, Vol.192 (6), p.1031-1034

2021

Volltextzugriff (PDF)

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

Blood, 2023-11, Vol.142 (Supplement 1), p.3257-3257

2023

Volltextzugriff (PDF)

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy

Expert review of molecular diagnostics, 2018-07, Vol.18 (7), p.675-683

2018

Volltextzugriff (PDF)

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma

British journal of haematology, 2024-02, Vol.204 (2), p.514-524

2024

Volltextzugriff (PDF)

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

Blood, 2021-11, Vol.138 (Supplement 1), p.3504-3504

2021

Volltextzugriff (PDF)

Circulating tumor DNA of classical Hodgkin lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7516-7516

2023

Volltextzugriff (PDF)

Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

British journal of haematology, 2019-11, Vol.187 (4), p.478-487

2019

Volltextzugriff (PDF)

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Hematological oncology, 2024-11, Vol.42 (6), p.e3312

2024

Volltextzugriff (PDF)

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Journal of clinical oncology, 2024-08

2024

Volltextzugriff (PDF)

CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival

Radiologia medica, 2023-12, Vol.128 (12), p.1497-1507

2023

Volltextzugriff (PDF)

Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

Hematological oncology, 2022-02, Vol.40 (1), p.11-21

2022

Volltextzugriff (PDF)

Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience

Blood, 2018-11, Vol.132 (Supplement 1), p.5669-5669

2018

Volltextzugriff (PDF)

Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)

Anticancer research, 2019-07, Vol.39 (7), p.3893-3899

2019

Volltextzugriff (PDF)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

Cancers, 2022-02, Vol.14 (4), p.1018

2022

Volltextzugriff (PDF)

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood, 2017-12, Vol.130, p.5098-5098

2017

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(34)
Berichte
(2)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Hematology
(13)
Humans
(13)
Oncology
(11)
Lymphoma
(7)
Patients
(6)
Targeted Cancer Therapy
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Female
(5)
Prognosis
(5)
Aged
(4)
Antineoplastic Agents - Therapeutic Use
(4)
B-Cell Lymphoma
(4)
Chemotherapy
(4)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(4)
Male
(4)
Middle Aged
(4)
Survival
(4)
Treatment Outcome
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(5)
Hematological Oncology
(4)
British Journal Of Haematology
(3)
Blood Advances
(2)
Chemotherapy
(2)
Clinical Lymphoma, Myeloma And Leukemia
(2)
Haematologica
(2)
Hemasphere
(2)
Journal Of Clinical Oncology
(2)
Annals Of Hematology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

Lymphomas in pregnancy

Bacterial infection-driven lymphomagenesis

Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

Circulating tumor DNA of classical Hodgkin lymphoma

Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival

Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience

Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Suchergebnisse filtern